Patents by Inventor Sabrina Kneissl

Sabrina Kneissl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high throughput screening
    Patent number: 10415057
    Abstract: The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus Morbillivirus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation of morbillivirus F and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: September 17, 2019
    Assignee: BUNDERSREPUBLIK DEUTSCHLAND, LETZVERTRETEN DURCH DEN PRÄSIDENTEN DES PAUL-EHRLICH-INSTITUTS
    Inventors: Christian Buchholz, Sabrina Kneissl, Klaus Cichutek, Roberto Cattaneo
  • PSEUDOTYPING OF RETROVIRAL VECTORS, METHODS FOR PRODUCTION AND USE THEREOF FOR TARGETED GENE TRANSFER AND HIGH THROUGHPUT SCREENING
    Publication number: 20180201954
    Abstract: The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus Morbillivirus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation of morbillivirus F and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.
    Type: Application
    Filed: December 22, 2017
    Publication date: July 19, 2018
    Inventors: Christian Buchholz, Sabrina Kneissl, Klaus Cichutek, Roberto Cattaneo